Jade Biosciences Doses First Patient in Phase 2 Study of Kidney Disease Therapy
MT Newswires Live
May 26
Jade Biosciences (JBIO) has dosed the first participant in its phase 2 trial of experimental therapy, JADE101, for immunoglobulin A nephropathy, or IgAN, the drugmaker said Tuesday.
IgAN is a chronic autoimmune kidney disease that can progress to kidney failure over time, often affecting younger patients.
The open-label study will enroll about 30 participants and evaluate safety, tolerability, kidney function and protein levels in urine as markers of disease progression, the company said.
Interim results are expected in 2027, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.